Impact of Daily Bathing With Chlorhexidine in the Critical Patient

The search for preventive measure with daily bathing with chlorhexidine in the critical care patient will result in a reduction in patient colonization with multidrug resistant pathogens. Thus, preventing healthcare associated infections. The aim of this study was to determine the impact of daily bathing with chlorhexidine in patient colonization, environment and healthcare workers in the medical intensive care unit (MICU).

The study will be conducted at the University Hospital "Dr. José Eleuterio González", a 450-bed teaching hospital in Monterrey, northeast Mexico.

This is a prospective, experimental, randomized, open-label, double blind study comparing chlorhexidine versus placebo. Any patient 18 years or older admitted to the MICU or with less than 48 hours of patient-days will be included. Patients who present burns with more than 20% body surface, pregnant patients and patients with allergy history to chlorhexidine.

Samples will be obtained from the patient, patient environment and healthcare personnel.

Sampling of the environment (bed rail, mechanical ventilator, table adjacent to the bed, etc.) and patient's anogenital and pharyngeal region will be collected with "swabbing" technique using cotton swabs and cultured according to Public Health England.

Patient skin sampling will be obtained from anorectal region, pharynx, axillary and inguinal fold collected with Williamson-Kligman technique. Colonies will then be further selected and properly cultivated according to their characteristics. Antibiotic susceptibility, clonal relationship, biofilm index and antibiotic susceptibility to chlorhexidine will be determined.

Demographics and clinical data will be collected from admission, throughout hospitalization and discharge.

Introduction:

The search for preventive measure with daily bathing with chlorhexidine in the critical care patient will result in a reduction in patient colonization with multidrug resistant pathogens. Thus, preventing healthcare associated infections. The aim of this study was to determine the impact of daily bathing with chlorhexidine in patient colonization, environment and healthcare workers in the medical intensive care unit (MICU).

Setting:

The study will be conducted at the University Hospital "Dr. José Eleuterio González", a 450-bed teaching hospital in Monterrey, northeast Mexico. The hospital has an average of 22 to 23 thousand yearly discharges with a 20 bed and 15 bed ICU for adults and pediatric/neonatal patients, respectively.

Design and methods:

This is a prospective, experimental, randomized, open-label, double blind study comparing chlorhexidine versus placebo. The randomization will occur 1:1 and the patients will be divided in two groups. The chlorhexidine group will receive daily baths with chlorhexidine wipes at 2% concentration (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México), plus oral spray with chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied. The placebo group, will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in the first arm.

Any patient 18 years or older admitted to the MICU or with less than 48 hours of patient-days will be included. Patients who present burns with more than 20% body surface, pregnant patients and patients with allergy history to chlorhexidine. Included patients who develop rash or pruritus after chlorhexidine baths, will be eliminated from the study.

Two weeks previous to the start of the study, MICU personnel will receive theoretical and practical training, were the bathing technique will be taught. Attendance of personnel will be recorded and skills will be surveiled during the intervention.

Bathing technique:

Before use, wipe packages will need to be heated in a conventional microwave for 10-12 seconds, under provider instructions. With the use of globes, the entire skin surface will be covered from the mandibular region to the feet, avoiding contact with mucous membranes such as anal, nasal or urethral membranes. A circular motion will be implemented during bathing.

For facial and genital region, wipes or wet dressings will allowed. The facial and genital region will be the first to clean. Mouthwashes with oral spray solution will be carried out, trying to properly impregnate cheeks, palate, pharynx and tongue, letting the solution sit for a minute before removal.

A towel wipe will be used for the neck and shoulders; using a side of the wipe for the anterior anatomical region and the other side for the posterior region. A wipe will be used for each limb (4 in total), using one side for the anterior region and the back side for the posterior region. A wipe will be designated to the buttocks and perianal region, avoiding the anal region. A wipe will be used for the torso, one for the dorsal region, one for the feet and one will be reserved for spare. For scalp washing, shampoo foam will be applied in a circular motion, trying to cover the entire surface of the scalp, excess will be removed with a dry towels.

Sampling:

Samples will be obtained from the patient and environment. Sampling of the environment (bed rail, mechanical ventilator, table adjacent to the bed, etc.) and patient's anogenital and pharyngeal region will be collected with "swabbing" technique using cotton swabs and cultured according to Public Health England.

Patient skin sampling will be obtained from anorectal region, pharynx, axillary and inguinal fold collected with Williamson-Kligman technique; delimiting an area of 3 cm2 and subsequent application of 1 ml a unionized solution, then proceed to gently scrape the area with a sterile spatula. This liquid is then retrieved with a pipette and cultured directly on a blood agar plate. Colonies will then be further selected and properly cultivated according to their characteristics.

Healthcare personnel samples will also be obtained from pharynx, skin and hands. All these samples will be collected the day of admission to the MICU, first 72 hours, 10th day and once a week until discharge of the patient. In the case of healthcare workers, will be collected at the end of their workday.

Isolate processing:

Samples will be cultured using conventional methods: from prime media, colonies will be taken separately and will be placed in a Brucella broth with 15% glycerol. Specimens will be then frozen to -80ºC.

When processing isolates, conventional phenotypic identification methods will be used. From primary isolate testing, corresponding biochemical tests will be selected for each species identification. When phenotypic tests don't reach isolate identification, molecular based testing and gene amplification will be used.

Antimicrobial susceptibility will be evaluated by the broth microdilution method and according to protocols M07-A10 and M100-S25 from Clinical and Laboratory Standards Institute (CLSI) guidelines and processed by an automatized system (SensititreAris 2X).

Pathogen clonal relationship For clonal relationship, pulsed filed gel electrophoresis will be used. Band pattern will be analyzed visually according to Tenover criteria. Data obtained will be analyzed with statistical software. Polymerase chain reaction (PCR) gene amplification will be obtained to analyze antibiotic resistance patterns for each species.

Pathogen biofilm production:

Biofilm production will be determined by crystal violet staining and a biofilm index will be obtained by spectrophotometry.

Pathogen susceptibility to chlorhexidine:

For determination of minimum inhibitory concentration (MIC) to chlorhexidine, agar dilution method will be applied according to protocol M07-A9 y M100-S20 in CLSI guidelines. Isolates with MIC values of ≥90, will be denoted with reduced susceptibility to such disinfectant.

Clinical data and follow-up:

Demographics and clinical data will be collected from admission, throughout hospitalization and discharge. Variables such as previous hospital admission in the previous year, previous surgeries, history of infection by resistant pathogens, days of hospital stay, instrumentation (use of foley catheter, mechanical ventilation or central venous catheter) and clinical evolution evaluated by Acute Physiology and Chronic Health Evaluation (APACHE-II) and Scale for the Assessment of Positive Symptoms (SAPS).

Positive culture swabs obtained from healthcare workers with resistant pathogens will proceed with reinforcement of hand hygiene and strengthening in universal protection (gloves, face mask, etc). If positive Methicillin-resistant Staphylococcus aureus (MRSA) culture is obtained, intranasal mupirocin treatment will be given for 5 days until a negative culture is achieved.

Hospital Epidemiology team's routine surveillance and monitoring will continue throughout the study period. Rate of healthcare associated infections will be compared to before, during and after intervention. Surveillance of healthcare associated infections will be following Center for Disease Control (CDC) guidelines.

Eligibility Criteria:
Inclusion Criteria:

* Any patient admitted to the medical intensive care unit
* Any patient with less than 48 hours in the medical intensive care unit
* Patient's age 18 years or older

Exclusion Criteria:

* Patients with burns greater than 20% body surface
* Pregnancy
* Patients with recorded allergy history to chlorhexidine

Elimination Criteria:

* Patient refuses participation in the study
* Patient develops severe reaction to chlorhexidine, defined as the sudden appearance of rash and/or pruritus.